Document:

Exhibit 10.1

Exhibit 10.1

IRIS INTERNATIONAL, INC

KEY EMPLOYEE AGREEMENT

FOR

RICHARD A. O’LEARY

IRIS INTERNATIONAL, INC., a Delaware corporation (the “Company”), agrees with you as follows:

1. Position and Responsibilities.

1.1 The Company will employ you and you shall serve in an executive capacity as Corporate Vice
President, Human Resources and Administration, and perform the duties customarily associated with
such capacity from time to time as the Company shall reasonably designate or as shall be reasonably
appropriate and necessary in connection with such employment. You will commence service in this
capacity on the date set forth in Section 2.1 below.

1.2 Subject to Section 4 below, you will, to the best of your ability, devote your
full time and best efforts to the performance of your duties hereunder and the business and affairs
of the Company. You will report to the Company’s Chief Executive Officer.

1.3 You will duly, punctually and faithfully perform and observe any and all rules and
regulations which the Company may now or shall hereafter establish governing the conduct of its
business, except to the extent that such rules and regulations may be inconsistent with your
executive position.

2. Term of Employment; Termination.

2.1 The commencement date of your employment shall be February 14, 2011 (your “Start Date”).

2.2 Unless otherwise mutually agreed in writing, this Agreement and your employment by the
Company pursuant to this Agreement shall be terminated on the earliest of:

(a) your death, or any illness, disability or other incapacity that renders you physically
unable regularly to perform your duties hereunder for a period in excess of one hundred twenty
(120) consecutive days or more than one hundred eighty (180) days in any consecutive twelve (12)
month period;

(b) thirty (30) days after you, for any reason, give written notice to the Company of your
resignation; or

(c) immediately if the Company, with or without cause, gives written notice to you of your
termination.

2.3 The determination regarding whether you are physically unable regularly to perform your
duties (as described in Section 2.2(a)) shall be made by the Board of Directors.

 

 

 

2.4 Any notice required pursuant to this Section 2 shall be given in accordance with
the provisions of Section 9 hereof. The exercise of either party’s right to terminate this
Agreement pursuant to Sections 2.2(b) or (c) is not exclusive and shall not effect
either party’s right to seek remedies for the other party’s breach, if any, giving rise to such
termination.

2.5 You may be terminated with or without cause. If you are terminated without cause, you
will be entitled to certain severance benefits as described in this Agreement. You shall be deemed
terminated “for cause” if, in the reasonable determination of the Company, you (a) commit an act
that is fraudulent, dishonest or a material breach of the Company’s policies, including wrongful
disclosure of any trade secrets or other confidential information of the Company, or material
breach of Section 4 of this Agreement or any material provision of the Employee
Confidentiality Agreement (as defined in Section 5), (b) are convicted of a felony under
federal, state, or local law applicable to the Company or (c) intentionally refuse, without proper
cause, to substantially perform duties after a demand for such performance has been delivered in
writing by the Company’s Chief Executive Officer or the Board of Directors, which notice shall
specify the alleged instance of breach, and shall provide you with reasonable time in which to
remedy such breach.

3. Compensation; Benefits; and Investment Rights.

3.1 The Company shall pay to you for the services to be rendered hereunder a base salary at an
annual rate of $235,000 subject to increases in accordance with the policies of the Company, as
determined by its Board of Directors, in force from time to time, payable in installments in
accordance with Company policy. You shall also be entitled to all rights and benefits for which
you shall be eligible under bonus, pension, group insurance, long-term disability, life insurance,
profit-sharing and other Company benefits which may be in force from time to time and provided
specifically to you or for the Company’s executive officers generally.

3.2 You will be awarded a 7 year stock option to purchase up to 22,500 shares of the Company’s
Common Stock. The option shall be issued pursuant to the Company’s 2007 Stock Incentive Plan, have
an exercise price equal to the per share fair market value of the Company’s Common Stock on the
date of grant, vest over 4 years, 25% on the first anniversary of your Start Date and thereafter
6.25% will vest in equal quarterly installments, and otherwise be issued on terms consistent with
the Company’s standard form of stock option agreement. Additionally, you will be awarded a
restricted stock unit for 9,000 shares of the Company’s Common Stock, which restricted stock unit
shall vest over 4 years, 25% of which will vest on a date which is 13 months following your Start
Date and thereafter 6.25% will vest in equal quarterly installments, and otherwise be issued on
terms consistent with the Company’s standard form of restricted stock unit agreement. In addition
to the foregoing, you will be eligible for further option and/or equity awards, commensurate with
other similar situated employees, based on your performance as determined by the CEO and the
Compensation Committee of the Board of Directors.

3.3 You shall also be eligible for an annual bonus to be determined by the CEO and
Compensation Committee of the Board of Directors in accordance with the Company’s bonus program for
executive officers. The bonus program provides for cash and stock-based
compensation, with the stock-based compensation comprised of stock options and restricted
stock unit awards.

 

2

 

3.4 You shall be entitled to four (4) weeks of paid vacation per year to be taken at such time
as will not interfere with the performance of your duties. You will also be entitled to illness
days during the term of this Agreement consistent with the Company’s standard practice for its
employees generally as in effect from time to time.

3.5 (a) Except as provided in subsection (b) below, in the event that (i) your employment is
terminated by the Company without cause at any time pursuant to Section 2.2(c) hereof or by
you for Good Reason (as defined herein), and (ii) you deliver to the Company on or before the
thirtieth (30th) day following the date your employment is terminated a signed
settlement agreement and general release in the form attached hereto as Exhibit A (the
“Release”) and (iii) you satisfy all conditions to make the Release effective, then the Company
shall pay you, at the time and in the manner specified in subsection (c) below, an amount equal to
one (1) times your annual base salary in effect immediately prior to such termination.

(b) If a Change in Control (as defined herein) occurs and at any time within the three (3)
months before or eighteen (18) months after the effective date of the Change in Control your
employment is terminated by the Company without cause pursuant to Section 2.2(c) hereof or
by you for Good Reason, then, in lieu of the payments provided for in subsection (a) above and
provided that you deliver to the Company on or before the thirtieth (30th) day following
the date your employment is terminated a signed Release and satisfy all conditions to make the
Release effective:

(i) the Company shall pay you, at the time and in the manner specified in subsection
(c) below, an amount equal to one and one-half (1.5) times your annual base salary in effect
immediately prior to such termination;

(ii) the Company shall pay you, at the time and in the manner specified in subsection
(c) below, an amount equal to one and one-half (1.5) times your Average Cash Bonus, where
“Average Cash Bonus” is equal to (A) the sum of the annual cash bonus actually paid to you
for performance during the two fiscal years immediately preceding the date of your
termination for which the Company has paid bonuses to executives, divided by (B) two (2).
For purposes of clarity, if you did not receive a bonus during either or both of the
immediately preceding two fiscal years for which the Company has paid annual cash bonuses to
executives, either because you were not then employed by the Company or for any other
reason, then a value of zero shall be assigned as your bonus for such fiscal year for
purposes of calculating the Average Cash Bonus;

(iii) you shall be entitled to full vesting and exercisability of all unvested stock
options, restricted stock, restricted stock units and all other equity compensation awards;
and

 

3

 

(iv) you shall be entitled to continue to receive for a period of eighteen (18) months
following termination of your employment, the health and welfare
benefits you were receiving as of the date of termination of your employment, at the
same cost to you and your dependents (as applicable) as such health and welfare benefits
cost immediately prior to such termination of employment (subject to premium increases
affecting participants in such plan(s) generally); provided, that if the Company determines,
in its sole discretion, that it is necessary or advisable for you to elect continuation
healthcare coverage under Section 4980B of the Code and the regulations thereunder in order
for the Company to provide such coverage under its healthcare plans, and the Company so
notifies you, you hereby agree to make such an election; and provided further, that if the
Company determines, in its sole discretion, that it is unable to continue to provide you
with any other health and welfare benefits under its health and welfare plans, and the
Company so notifies you, in lieu of providing you continued coverage under such plans the
Company will either obtain for you comparable coverage under another plan for which you
qualify or reimburse you for your cost to obtain comparable coverage directly.

(c) The Company shall make payment of the amounts specified in subsection (a) or, if
applicable, clauses (i) and (ii) of subsection (b) as follows:

(i) an amount that does not exceed two times the maximum amount that may be taken into
account under a qualified plan pursuant to section 401(a)(17) of the Internal Revenue Code
(the “Code”) for the year in which such termination occurs, shall be made, at the Company’s
option, (A) in the form of a lump sum payment within ten (10) days of the date you become
entitled to receive such amounts or (B) through regular payroll payments in equal amounts
for a period that begins in the month of termination and ends no later than, in the case of
payments made pursuant to subsection (a), twelve (12) months after the month of termination
and, in the case of payments made pursuant to subsection (b), eighteen (18) months after the
month of termination; and

(ii) the positive amount, if any, that is the difference between the amounts to which
you are entitled pursuant to subsection (a) or, if applicable, clauses (i) and (ii) of
subjection (b) and the amount determined under clause (i) of this subsection (c), shall be
made, at the Company’s option, (A) in the form of a lump sum payment within ten (10) days of
the date you become entitled to receive such amounts or (B) through regular payroll payments
in equal amounts for a period that begins in the month of termination and ends no later than
the fifteenth (15th) day of the third (3rd) month of the calendar year
following the year in which you are terminated.

The parties intend that the compensation payable pursuant to clause (ii) of this subsection (c)
shall be treated as a short-term deferral as that term is used in section 409A of the Code and the
regulations promulgated thereunder (collectively, “Section 409A”). The parties intend that each of
the payments payable pursuant to clause (i) of this subsection (c) shall be treated as a separate
payment for purposes of Section 409A and excluded from the definition of “deferred compensation”
pursuant to the regulations promulgated thereunder regarding separation pay payable upon an
involuntary separation from service.

 

4

 

(d) For purposes of this Section 3.5:

(i) “Change in Control” shall mean (A) the dissolution or liquidation of the Company,
(B) approval by the stockholders of the Company of any sale, lease, exchange or other
transfer (in one or a series of transactions) of all or substantially all of the assets of
the Company, (C) approval by the stockholders of the Company of any merger or consolidation
of the Company in which the holders of voting stock of the Company immediately before the
merger or consolidation will not own thirty five percent (35%) or more of the voting stock
of the continuing or surviving corporation immediately after such merger or consolidation;
or (D) a change of fifty percent (50%) (rounded to the next whole person) in the membership
of the Board within a twelve (12)-month period, unless the election or nomination for
election by stockholders of each new director within such period was approved by the vote of
a majority of the directors then still in office who were in office at the beginning of the
twelve (12)-month period; and

(ii) “Good Reason” shall mean any of the following (without your express written
consent and provided you provide written notice within ninety (90) days of the initial
occurrence stating in reasonable detail the basis for termination, a thirty (30)-day
opportunity to cure to the Company, and your actual separation from service occurs within
two (2) years from said initial occurrence): (A) a material reduction in your
responsibilities or duties as such responsibilities or duties exist on the date hereof,
except in the event of a termination for cause, death or disability or your resignation
other than for Good Reason; (B) a material reduction of your base salary as it exists on the
date hereof (i.e., a reduction of your base salary unless such reduction (x) is in
connection with concurrent and proportional reductions in the salaries of other members of
management of the Company, which reductions have been approved by the Board, and (y) reduces
your base salary to no less than 80% of your base salary immediately before such reduction);
or (C) any material relocation by the Company of your place of employment that would
increase your one-way commute to the place of employment by more than fifty (50) miles when
compared to your commute immediately prior to the relocation.

(e) Notwithstanding any provision of this Agreement to the contrary, if the Company
determines, based upon the advice of the tax advisors for the Company, that part or all of the
consideration, compensation or benefits to be paid to you pursuant to this Agreement constitute
“parachute payments” under Section 280G(b)(2) of the Code, then, if the aggregate present value of
such parachute payments, singularly or together with the aggregate present value of any
consideration, compensation or benefits to be paid to you under any other plan, arrangement or
agreement which constitute “parachute payments” (collectively, the “Parachute Amount”) exceeds 2.99
times your “base amount,” as defined in Section 280G(b)(3) of the Code (the “Base Amount”), the
amounts constituting “parachute payments” which would otherwise be payable to you or for your
benefit shall be reduced to the extent necessary so that the Parachute Amount is equal to 2.99
times the Base Amount (the “Reduced Amount”); provided, however, that the Company shall pay to you
the Parachute Amount without reduction if the Company determines that payment of the Parachute
Amount would generate more after-tax income to you than the Reduced Amount. In the event of a
reduction of the payments that would

 

5

 

otherwise be paid to you, then the Company may elect which and
how much of any particular entitlement shall be eliminated or reduced and shall notify you promptly of such election; provided, however, that
the aggregate reduction shall be no more than as set forth in the preceding sentence of this clause
(e). Within ten (10) days following such election, the Company shall pay you such amounts as are
then due pursuant to this Agreement and shall pay you in the future such amounts as become due
pursuant to this Agreement. As a result of the uncertainty in the application of Section 280G of
the Code at the time of a determination hereunder, it is possible that payments will be made by the
Company which should not have been made (“Overpayment”) or that additional payments which are not
made by the Company pursuant to this clause (e) should have been made (“Underpayment”). In the
event of a final determination by the Internal Revenue Service, a final determination by a court of
competent jurisdiction or a change in the provisions of the Code or regulations or tax law, that an
Overpayment has been made, any such Overpayment shall be treated for all purposes as a loan to you
that you shall repay to the Company together with interest at the applicable federal rate provided
for in Section 7872(f)(2) of the Code. In the event of a final determination by the Internal
Revenue Service, a final determination by a court of competent jurisdiction or a change in the
provisions of the Code or regulations or tax law pursuant to which an Underpayment arises under
this Agreement, any such Underpayment shall be promptly paid by the Company to you or for your
benefit, together with interest at the applicable federal rate provided for in Section 7872(f)(2)
of the Code.

3.6 The Company will pay and/or reimburse you for the following costs associated with your
relocation from Painted Post, New York to Los Angeles County or Ventura County, California: (i)
reasonable and customary moving expenses (including packing and shipping) for you and your family
and your customary household possessions (excluding automobiles); (ii) use of a furnished corporate
apartment in Los Angeles or Ventura County, California for up to six (6) months following your
Start Date, such expense not to exceed $25,000; and (iii) third party costs (including real estate
sales commissions) incurred in connection with the sale at any time within the twenty four (24)
months following your Start Date of your primary residence in Painted Post, New York and the
purchase of your primary residence in Los Angeles or Ventura County, California, not to exceed
$75,000. To the extent all or any portion of the $75,000 payment or reimbursement is considered
taxable income to you, the Company will also pay or reimburse you such additional amounts as are
necessary for you to pay your tax liabilities with respect to such taxable income. All such costs
incurred by you shall be documented and submitted to the Company for reimbursement in accordance
with the Company’s standard expense reimbursement policies. You shall not be entitled to payment
or reimbursement of any such costs incurred following termination of your employment.

4. Other Activities During Employment.

4.1 Except with the prior written consent of the Company’s Board of Directors, you will not
during the term of this Agreement undertake or engage in any other employment, occupation or
business enterprise, other than ones in which you are a passive investor in non-competitive
businesses. You may engage in civic and not-for-profit activities so long as such activities do
not materially interfere with the performance of your duties hereunder.

4.2 Except as permitted by Section 4.3, you will not acquire, assume or participate
in, directly or indirectly, any position, investment or interest, known by you to be
adverse or antagonistic to, or competitive with, the Company, its businesses or prospects,
financial or otherwise.

 

6

 

4.3 During the term of your employment by the Company (except on behalf of the Company), you
will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor,
associate, representative, consultant, or in any capacity whatsoever engage in, become financially
interested in, be employed by or have any business connection with any other person, corporation,
firm, partnership or other entity whatsoever which were known by you to directly or indirectly
compete with the Company, throughout the world, in any line of business engaged in (or planned to
be engaged in) by the Company; provided, however, that anything above to the contrary
notwithstanding, you may own, as a passive investor, securities of any competitor corporation, so
long as your direct holdings in any one such corporation shall not in the aggregate constitute more
than 1% of the publicly-traded voting stock of such corporation.

5. Proprietary Information and Inventions. You agree to sign and be bound by the provisions of
the Company’s standard Employee Confidentiality and Inventions Agreement (the “Employee
Confidentiality Agreement”).

6. Remedies. Your duties under the Employee Confidentiality Agreement shall survive
termination of your employment with the Company. You acknowledge that a remedy at law for any
breach or threatened breach by you of the provisions of the Employee Confidentiality Agreement
would be inadequate and you therefore agree that the Company shall be entitled to injunctive relief
in case of any such breach or threatened breach.

7. Assignment. Neither this Agreement nor any rights or obligations hereunder may be assigned
by you.

8. Severability. In case any one or more of the provisions contained in this Agreement shall,
for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect the other provisions of this Agreement, and this
Agreement shall be construed as if such invalid, illegal, or unenforceable provision had never been
contained herein. If moreover, any one or more of the provisions contained in this Agreement shall
for any reason be held to be excessively broad as to duration, geographical scope, activity or
subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent
compatible with the applicable law as it shall then appear.

9. Notices. Any notice which the Company is required or may desire to give you shall be given
by personal delivery or registered or certified mail, return receipt requested, addressed to you at
the address of record with the Company, or at such other place as you may from time to time
designate in writing. Any notice which you are required or may desire to give to the Company
hereunder shall be given by personal delivery or by registered or certified mail, return receipt
requested, addressed to the Company’s Chief Executive Officer, at the Company’s principal office or
at such other office as the Company may from time to time designate in writing. The date of
personal delivery or the date of mailing any such notice shall be deemed to be the date of delivery
thereof.

 

7

 

10. Waiver. If either party should waive any breach of any provisions of this Agreement, he or
it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any
other provision of this Agreement.

11. Complete Agreement; Amendments. The foregoing, together with the Employee Confidentiality
Agreement, is the entire agreement of the parties with respect to the subject matter hereof and
thereof and may not be amended, supplemented, canceled or discharged except by written instrument
executed by both parties hereto.

12. Headings. The headings of the sections hereof are inserted for convenience only and shall
not be deemed to constitute a part hereof nor to affect the meaning thereof.

13. Choice of Law. All questions concerning the construction, validity and interpretation of
this Agreement will be governed by the laws of the State of California, without giving effect to
any choice of law principles.

14. Section 409A of the Internal Revenue Code — General Provisions.

14.1 It is the intention of the Company and you that this Agreement shall comply with the
requirements of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”). All
payments under this Agreement are intended to be excluded from the requirements of Section 409A or
be payable on a fixed date or schedule under Section 409A. All payments made under this Agreement
shall be strictly paid in accordance with the terms of this Agreement. To the extent that this
Agreement is subject to Section 409A, notwithstanding the other provisions hereof, all provisions
herein, or incorporated by reference, shall be construed and interpreted to comply with Section
409A. Each payment of compensation under this Agreement shall be treated as a separate payment of
compensation for purposes of Section 409A.

14.2 Any discretionary bonuses that you may be awarded by the Company shall be paid no later
than the fifteenth (15th) day of the third (3rd) month following the year in
which the services were rendered with respect to which the discretionary bonus has been determined.

14.3 Any reimbursements or in-kind benefits provided under this Agreement that are subject to
Section 409A shall be made or provided in accordance with the requirements of Section 409A,
including, where applicable, the requirement that (i) any reimbursement is for expenses incurred
during the period of time specified in this Agreement, (ii) the amount of expenses eligible for
reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses
eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii)
the reimbursement of an eligible expense will be made no later than the last day of the calendar
year following the year in which the expense is incurred, and (iv) the right to reimbursement or
in-kind benefits is not subject to liquidation or exchange for another benefit.

 

8

 

14.4 Notwithstanding anything to the contrary herein, (i) if at the time of your “separation
from service” with the Company you are a “specified employee” (as such terms are defined in Section
409A and any regulations or other pronouncements thereunder) and the deferral of the commencement
of any payments or benefits otherwise payable hereunder as a
result of such termination of employment is necessary in order to prevent any accelerated or
additional tax under Section 409A, then the Company will defer the commencement of the payment of
any such payments or benefits hereunder (without any reduction in such payments or benefits
ultimately paid or provided to you) until the date that is six months and one day following your
separation from service with the Company (or the earliest date that is permitted under Section
409A).

14.5 Notwithstanding anything to the contrary in this Agreement, the Company shall not make
any deductions for money or property that you owe to the Company, or offset or otherwise reduce any
sums that may be due or become payable to or for your account, from amounts that constitute
“deferred compensation” for purposes of Section 409A.

14.6 Your right to any “deferred compensation,” as defined under Section 409A, shall not be
subject to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment,
garnishment by creditors, or borrowing, to the extent necessary to avoid tax, penalties and/or
interest under Section 409A.

[Signatures on Following Page]

 

9

 

IN WITNESS WHEREOF, the parties have executed this Key Employee Agreement on the day and year
written below.

	 	 	 	 	 	 	 
	 	 	IRIS INTERNATIONAL, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ César M. García	 	 
	 

	 	 	 	 

Name: César M. García
	 	 
	 

	 	 	 	Its: Chief Executive Officer	 	 
	 

	 	 	 	Dated: February 14, 2011	 	 

ACCEPTED AND AGREED TO

THIS 14th DAY OF FEBRUARY, 2011

	 	 	 
	/s/ Richard A. O’Leary
	 	 
	 

Richard A. O’Leary

	 	 

 

10

 

EXHIBIT A

[IRIS LETTERHEAD]

RELEASE

[DATE]

Richard A. O’Leary

[ADDRESS]

	 	 	 	Re: Separation Terms and General Release Agreement

Dear Mr. O’Leary:

This letter confirms the terms of your separation from the employment of IRIS International, Inc.
and consideration in exchange for your waiver and general release of claims in favor of IRIS
International, Inc. and its officers, directors, employees, agents, representatives, subsidiaries,
divisions, affiliated companies, successors, and assigns (collectively, the “Company” or “IRIS”).

1. Termination Date. Your employment with the Company will end effective                                          (the
“Termination Date”). Between now and the Termination Date, you should assist with any
transition-related activities as directed by the employee to whom you directly report.

2. Acknowledgment of Payment of Wages. On or before execution of this release, we delivered to
you a final paycheck that includes payment for all accrued wages, salary, accrued and unused
vacation time, reimbursable expenses, and any similar payments due and owing to you from the
Company as of the Termination Date (collectively referred to as “Wages”). You are entitled to
these Wages regardless of whether you sign this Separation Terms and General Release Agreement (the
“Agreement”).

3. Consideration For Release. In consideration of the waiver and release of claims set forth
in Paragraphs 7 and 8 below, and in exchange for your signing this Agreement, the Company agrees to
provide you with the post-termination payments (the “Severance Payments”) described in Section 3.5
of that certain IRIS International, Inc. Key Employee Agreement for Richard A. O’Leary, dated
February 14, 2011. The Severance Payments are in addition to any amounts owed to you by the
Company. You acknowledge and agree that you are not otherwise entitled to receive the Severance
Payments. You understand that if you do not sign the Agreement, or if you revoke the signed
Agreement as described in Paragraph 19 below (if applicable), the Company has no obligation to
provide you with the Severance Payments.

4. COBRA Continuation Coverage. Your Company provided health coverage will end on your
Termination Date. If you are eligible for, and timely elect COBRA continuation, you may continue
health coverage pursuant to the terms and conditions of COBRA at your own expense. Our Human
Resources Department will contact you shortly after your Termination Date. All other insured
benefit coverage (e.g., life insurance, disability insurance) will also end on your Termination
Date.

 

 

 

5. Return of Company Property. By signing below, you represent that you have returned all the
Company property and data of any type whatsoever that was in your possession or control.

6. Confidential Information. You hereby acknowledge that as a result of your employment with
the Company you have had access to the Company’s confidential information. You acknowledge your
continuing obligations under the Employee Confidentiality Agreement you have previously executed,
and you agree you will hold all such confidential information in strictest confidence and that you
may not make any use of such confidential information. You further confirm that you have delivered
to the Company all documents and data of any nature containing or pertaining to such Confidential
Information and that you have not taken with you any such documents or data or any copies thereof.

7. General Release and Waiver of Claims.

7.1. The payments and agreements set forth in this Agreement fully satisfy any and all accrued
salary, vacation pay, bonus and commission pay, stock-based compensation, profit sharing,
termination benefits or other compensation to which you may be entitled by virtue of your
employment with the Company or your termination of employment. You acknowledge that you have no
claims and have not filed any claims against the Company based on your employment with or the
separation of your employment with the Company.

7.2. To the fullest extent permitted by law, you hereby release and forever discharge the
Company, its successors, subsidiaries and affiliates, directors, shareholders, current and former
officers, agents and employees (all of whom are collectively referred to as “Releasees”) from any
and all existing claims, demands, causes of action, damages and liabilities, known or unknown, that
you ever had, now have or may claim to have had arising out of or relating in any way to your
employment or separation from employment with the Company including, without limitation, claims
based on any oral, written or implied employment agreement, claims for wages, bonuses, commissions,
stock-based compensation, expense reimbursement, and any claims that the terms of your employment
with the Company, or the circumstances of your separation, were wrongful, in breach of any
obligation of the Company or in violation of any of your rights, contractual, statutory or
otherwise. Each of the Releasees is intended to be a third party beneficiary of the General Release
and Waiver of Claims set forth in this Paragraph 7.

(a) Release of Statutory and Common Law Claims. Such rights include, but are not limited to,
your rights under the following federal and state statutes: the Employee Retirement Income Security
Act (ERISA) (regarding employee benefits); the Occupational Safety and Health Act (safety matters);
the Family and Medical Leave Act of 1993; the Worker Adjustment and Retraining Act (“WARN”)
(notification requirements for employers who are curtailing or closing an operation) and common
law; tort; wrongful discharge; public policy; workers’ compensation retaliation; tortious
interference with contractual relations, misrepresentation, fraud, loss of consortium; slander,
libel, defamation, intentional or negligent infliction of emotional distress; claims for wages,
bonuses, commissions, stock-based compensation or fringe benefits; vacation pay; sick pay;
insurance reimbursement, medical expenses, and the like.

 

2

 

(b) Release of Discrimination Claims. You understand that various federal, state and local
laws prohibit age, sex, race, disability, benefits, pension, health and other forms of
discrimination, harassment and retaliation, and that these laws can be enforced through the U.S.
Equal Employment Opportunity Commission, the National Labor Relations Board, the Department of
Labor, and similar state and local agencies and federal and state courts. You understand that if
you believe your treatment by the Company violated any laws, you have the right to consult with
these agencies and to file a charge with them. Instead, you have decided voluntarily to enter into
this Agreement, release the claims and waive the right to recover any amounts to which you may have
been entitled under such laws, including but not limited to, any claims you may have based on age
or under the Age Discrimination in Employment Act of 1967 (ADEA; 29 U.S.C. Section 621 et. seq.)
(age); the Older Workers Benefit Protection Act (“OWBPA”) (age); Title VII of the Civil Rights Act
of 1964 (race, color, religion, national origin or sex); the 1991 Civil Rights Act; the Vocational
Rehabilitation Act of 1973 (disability); The Americans with Disabilities Act of 1990 (disability);
42 U.S.C. Section 1981, 1986 and 1988 (race); the Equal Pay Act of 1963 (prohibits pay
differentials based on sex); the Immigration Reform and Control Act of 1986; Executive Order 11246
(race, color, religion, sex or national origin); Executive Order 11141 (age); Vietnam Era Veterans
Readjustment Assistance Act of 1974 (Vietnam era veterans and disabled veterans); and California
state statutes and local laws of similar effect.

7.3. Releasees and you do not intend to release claims (i) which you may not release as a
matter of law (including, but not limited to, indemnification claims under applicable law); (ii)
for unemployment, state disability and/or paid family leave insurance benefits pursuant to the
terms of applicable state law; (iii) for any benefit entitlements that are vested as of the
Termination Date pursuant to the terms of a Company-sponsored benefit plan governed by the federal
law known as “ERISA”; and (iv) for vested stock and/or vested option shares pursuant to the written
terms and conditions of your existing stock and stock option grants and agreements existing as of
the Termination Date. To the fullest extent permitted by law, any dispute regarding the scope of
this general release shall be determined by an arbitrator under the procedures set forth in
paragraph 12.

8. Waiver of Unknown Claims. You expressly waive any benefits of Section 1542 of the Civil
Code of the State of California (and any other laws of similar effect), which provides:

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR
SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR.”

 

3

 

9. Covenant Not to Sue.

9.1. To the fullest extent permitted by law, you agree that you will not now or at any time in
the future pursue any charge, claim, or action of any kind, nature and character whatsoever against
any of the Releasees, or cause or knowingly permit any such charge, claim or
action to be pursued, in any federal, state or municipal court, administrative agency,
arbitral forum, or other tribunal, arising out of any of the matters covered by paragraphs 7 and 8
above.

9.2. You further agree that you will not pursue, join, participate, encourage, or directly or
indirectly assist in the pursuit of any legal claims against the Releasees, whether the claims are
brought on your own behalf or on behalf of any other person or entity.

9.3. Nothing in this paragraph shall prohibit you from: (1) providing truthful testimony in
response to a subpoena or other compulsory legal process, and/or (2) filing a charge or complaint
with a government agency such as the Equal Employment Opportunity Commission, the National Labor
Relations Board or applicable state anti-discrimination agency.

10. Non-disparagement. You agree that you will not make any statement, written or oral, or
engage in any conduct that is or could reasonably be construed to be disparaging of the Company or
its products, services, agents, representatives, directors, officers, shareholders, attorneys,
employees, vendors, affiliates, successors or assigns, or any person acting by, through, under or
in concert with any of them. Nothing in this paragraph shall prohibit you from providing truthful
testimony in response to a subpoena or other compulsory legal process.

11. Legal and Equitable Remedies. You and the Company agree that either party shall have the
right to enforce this Agreement and any of its provisions by injunction, specific performance or
other equitable relief without prejudice to any other rights or remedies that either party may have
at law or in equity for breach of this Agreement.

12. Arbitration of Disputes. Except for claims for injunctive relief arising out of a breach
of the Employee Confidentiality Agreement, you and the Company agree to submit to mandatory binding
arbitration any future disputes between you and the Company, including any claim arising out of or
relating to this Agreement. By signing below, you and the Company waive any rights you and the
Company may have to trial by jury of any such claims. You agree that the American Arbitration
Association will administer any such arbitration(s) under its National Rules for the Resolution of
Employment Disputes, with administrative and arbitrator’s fees to be borne by the Company. The
arbitrator shall issue a written arbitration decision stating his or her essential findings and
conclusions upon which the award is based. A party’s right to review of the decision is limited to
the grounds provided under applicable law. The parties agree that the arbitration award shall be
enforceable in any court having jurisdiction to enforce this Agreement. This Agreement does not
extend or waive any statutes of limitations or other provisions of law that specify the time within
which a claim must be brought. Notwithstanding the foregoing, each party retains the right to seek
preliminary injunctive relief in a court of competent jurisdiction to preserve the status quo or
prevent irreparable injury before a matter can be heard in arbitration.

13. Attorneys’ Fees. If any legal action arises or is brought to enforce the terms of this
Agreement, the prevailing party shall be entitled to recover its reasonable attorneys’ fees, costs
and expenses from the other party, in addition to any other relief to which such prevailing party
may be entitled, except where the law provides otherwise. The costs and expenses that may be
recovered exclude arbitration fees pursuant to paragraph 12 above.

 

4

 

14. Confidentiality Provision. You agree to keep the contents, terms and conditions of this
Agreement confidential and not disclose them except to your spouse or domestic partner, attorneys,
accountant or as required by subpoena or court order.

15. Materiality of Breach. Any breach of the provisions contained in paragraphs 6 through 10
and/or 14 will be deemed a material breach of this Agreement.

16. No Admission of Liability. You agree that this Agreement is not an admission or evidence
of any wrongdoing or liability on the part of the Company, its representatives, attorneys, agents,
partners, officers, shareholders, directors, employees, subsidiaries, affiliates, divisions,
successors or assigns. This Agreement will be afforded the maximum protection allowable under
California Evidence Code Section 1152 and/or any other state or Federal provisions of similar
effect.

17. Indemnification. This Release shall not apply with respect to any claims arising under
your existing rights to indemnification and defense pursuant to (a) the articles and bylaws of the
Company for acts as a director and/or officer, (b) any indemnification agreement with IRIS, or (c)
your rights of insurance under any director and officer liability policy in effect covering the
Company’s directors and officers.

18. Review of Agreement. You may not sign this Agreement prior to your Termination Date. You
may take up to twenty-one (21) days from the date you receive this Agreement, or until your
Termination Date, whichever date is later, to consider this Agreement and release and, by signing
below, affirm that you were advised by this letter to consult with an attorney before signing this
Agreement and were given ample opportunity to do so. You understand that this Agreement will not
become effective until you return the original properly signed Agreement to IRIS Human Resources,
attention: Director of Human Resources, at the Company’s principal executive offices in Chatsworth,
California, and after expiration of the revocation period without revocation by you.

[IF EMPLOYEE IS OVER 40 AT THE TIME OF TERMINATION, THE FOLLOWING SECTION 19 APPLIES:

19. Revocation of Agreement. You acknowledge and understand that you may revoke this
Agreement by faxing a written notice of revocation to our Human Resources Department, Attention
Director of Human Resources at (818)                                          any time up to seven (7) days after you sign
it. After the revocation period has passed, however, you may no longer revoke your Agreement.

 

5

 

IF EMPLOYEE IS UNDER 40 AT THE TIME OF TERMINATION, THE FOLLOWING SECTION 19 APPLIES:

19. Intentionally Omitted.]

20. Entire Agreement. This Agreement together with the Employee Confidentiality Agreement
that you previously executed is the entire Agreement between you and the Company with respect to
the subject matter of this Agreement and supersedes all prior negotiations and agreements, whether
written or oral, relating to this subject matter. You acknowledge that
neither the Company, nor its agents or attorneys, made any promise or representation, express
or implied, written or oral, not contained in this Agreement to induce you to execute this
Agreement. You acknowledge that you have signed this Agreement knowingly, voluntarily and without
coercion, relying only on such promises, representations and warranties as are contained in this
document. You understand that you do not waive any right or claim that may arise after the date
this Agreement is executed.

21. Modification. By signing below, you acknowledge your understanding that this Agreement
may not be altered, amended, modified, or otherwise changed in any respect except by another
written agreement that specifically refers to this Agreement, executed by the Company’s authorized
representatives and you.

22. Governing Law. This Agreement is governed by, and is to be interpreted according to, the
laws of the State of California.

23. Savings and Severability Clause. Should any court, arbitrator or government agency of
competent jurisdiction declare or determine any of the provisions of this Agreement to be illegal,
invalid or unenforceable, the remaining parts, terms or provisions shall not be affected thereby
and shall remain legal, valid and enforceable. Further, it is the intention of the parties to this
Agreement that, if a court, arbitrator or agency concludes that any claim under paragraph 7 above
may not be released as a matter of law, the General Release in paragraph 7 and the Waiver Of
Unknown Claims in paragraph 8 shall otherwise remain effective as to any and all other claims.

If this Agreement accurately sets forth the terms of your separation from the Company and if you
voluntarily agree to accept the terms of the severance package offered please sign below no earlier
than your Termination Date and return it to the Director of Human Resources.

PLEASE REVIEW CAREFULLY. THIS AGREEMENT CONTAINS

A GENERAL RELEASE OF KNOWN AND UNKNOWN CLAIMS.

Sincerely,

[NAME]

	 	 	 	 	 
	REVIEWED, UNDERSTOOD AND AGREED:	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

Richard A. O’Leary
	 	 
	Date:
	 	 	 	 
	 

	 	 

	 	 

DO NOT SIGN PRIOR TO YOUR TERMINATION DATE

 

6exv4w1

Exhibit 4.1

__________________________

SECOND SUPPLEMENTAL INDENTURE

Dated as of February 15, 2011

between

US ONCOLOGY, INC.,

and

WILMINGTON TRUST FSB,

as Trustee

to the

INDENTURE

Dated as of June 18, 2009

Among

US ONCOLOGY, INC.,

THE SUBSIDIARY GUARANTORS NAMED THEREIN

and

WILMINGTON TRUST FSB

as Trustee

9.125% SENIOR SECURED NOTES DUE 2017

__________________________

 

 

     THIS SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of
February 15, 2011, between US Oncology, Inc., a Delaware corporation (the “Company”), and
Wilmington Trust FSB, as trustee (together with its successors and assigns, in such capacity, the
“Trustee”).

WITNESSETH

     WHEREAS, the Company has heretofore executed and delivered an indenture, dated as of June 18,
2009 (the “Indenture”), between the Company, the subsidiary guarantors party thereto and
the Trustee, pursuant to which the Company has issued its 9.125% Senior Secured Notes due 2017
(collectively, the “Securities”);

     WHEREAS, the Company has called for redemption all of the outstanding Securities pursuant to
paragraph 5 of the form of Securities (the “Redemption”) at a redemption price equal to
100% of the principal amount of the Securities, plus the Applicable Premium (as defined in the
Indenture) and accrued and unpaid interest thereon to February 16, 2011 (the “Redemption
Date”);

     WHEREAS, immediately following the Redemption on the Redemption Date, the Company seeks to
discharge its obligations under the Indenture pursuant to Section 8.01(a), other than those
obligations that expressly survive such discharge pursuant to Section 8.01(c) and this Supplemental
Indenture;

     WHEREAS, the Company and the Holders of the Securities of at least a majority in aggregate
principal amount of the Securities currently outstanding have a dispute over the amount and
calculation of the Applicable Premium to be paid by the Company in connection with the Redemption,
and wish to resolve that dispute by the Court (as defined below);

     WHEREAS, Section 9.02 of the Indenture provides that, subject to certain conditions, the
Company and the Trustee may amend the Indenture or the Securities with the consent of the Holders
of at least a majority in aggregate principal amount of the Securities then outstanding;

     WHEREAS, the Company will deposit in an account with Wilmington Trust FSB, as securities
intermediary (the “Securities Intermediary”) for the benefit of the Holders of the
Securities as of the Redemption Date (together with their transferees, the “Eligible
Holders”), an aggregate amount of immediately available funds equal to $42,033,552.39 (the
“Escrow Funds”);

     WHEREAS, the Company desires to amend the Indenture to provide, among other things, that,
subject to and upon the terms and conditions set forth in this Supplemental Indenture, the
Securities Intermediary shall distribute the applicable portion, if any, of the Escrow Funds to the
Eligible Holders in accordance with their respective ownership of the Securities as of the
Redemption Date;

     WHEREAS, the Company desires to amend the Indenture to provide that the Company’s obligation
to pay any Contingent Redemption Payment survive the discharge of the Indenture;

     WHEREAS, Holders of at least a majority in aggregate principal amount of the Securities have
heretofore delivered their consents to the amendments set forth in this Supplemental Indenture; and

     WHEREAS, the Board of Directors of the Company has authorized and approved the execution and
delivery of this Supplemental Indenture.

1

 

     NOW, THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the
Trustee mutually covenant and agree for the equal and ratable benefit of the Holders as follows:

ARTICLE 1

CAPITALIZED TERMS

     Section 1.01 Capitalized Terms.

     Capitalized terms used herein but not defined herein shall have the meanings assigned to them
in the Indenture, including the form of Security for the Securities.

ARTICLE 2

AMENDMENTS

     Section 2.01 Article XIII.

     The Indenture shall be amended to add the following Article XIII:

“ARTICLE XIII

CONTINGENT REDEMPTION PAYMENT

     Section 13.01 Contingent Redemption Payment.

     (1) Prior to the Redemption, the Company shall cause the Escrow Funds to be deposited with
the Securities Intermediary in account 098559-000 in the name “US Oncology Custodial Account” (the
“Secured Escrow Account”).

     (2) In order to secure the full and punctual payment and performance of the Company’s
obligation to pay any Contingent Redemption Payment upon the Final Order of the Court, the Company
hereby grants to the Trustee, for the ratable benefit of the Eligible Holders, a continuing first
priority perfected security interest in all of the Company’s right, title and interest in and to
the Escrow Collateral, whether now owned or existing or hereafter acquired or arising, and
wherever located, and all proceeds of the foregoing.

     (3) Upon presentation, promptly after receipt thereof, to the Securities Intermediary by the
Trustee of the Final Order to the effect that the Contingent Redemption Payment is greater than
$0, the Trustee shall promptly direct the Securities Intermediary to disburse the Contingent
Redemption Payment to the Paying Agent for further distribution to the Eligible Holders. If the
funds in the Secured Escrow Account are insufficient to pay the Contingent Redemption Payment, the
Company shall pay to the Paying Agent for further distribution to the Eligible Holders any such
amount required to satisfy the Contingent Redemption Payment. Thereafter, the Trustee shall
promptly direct the Securities Intermediary to promptly turn over to the Company any remaining
funds in the Secured Escrow Account. The Company shall be entitled to a release to it of all
funds in the Secured Escrow Account upon presentation to the Securities Intermediary of the Final
Order (with a copy to the Trustee) to the effect that the Contingent Redemption Payment is $0.

2

 

     (4) At all times until the release of the Escrow Collateral in accordance with this Section
13.01 and the Securities Account Control Agreement, the Secured Escrow Account shall be
maintained. Amounts on deposit in the Secured Escrow Account shall be held in cash or, at the
written direction of the Company, invested (and reinvested from time to time) in U.S. Government
Obligations or money market funds investing in U.S. Government Obligations (such investments
collectively referred to herein as “Eligible Investments”), which Eligible Investments shall be
held in the Secured Escrow Account. Any income, including any interest or capital gains received
with respect to the balance from time to time standing to the credit of the Secured Escrow
Account, shall remain, or be deposited, in the Secured Escrow Account.

     (5) In the event that Holders of at least a majority in aggregate principal amount of the
Securities then outstanding fail to deliver to the Trustee by 5:00 p.m. New York City time on
February 18, 2011 medallion-stamped letters evidencing beneficial ownership of such Holders’
Securities in connection with a direction to the Trustee regarding the resolution of the dispute
concerning the amount and calculation of the Applicable Premium, the Trustee shall thereafter
promptly deliver a certification of such failure to the Company and direct the Securities
Intermediary to release and turn over all funds in the Secured Escrow Account to the Company.

     (6) Upon all of the funds in the Secured Escrow Account being released by the Securities
Intermediary to be used in the payment of the Contingent Redemption Payment or being released to
the Company, the security interests in the Escrow Collateral shall automatically terminate.

     Section 13.02 Certain Definitions. For purposes of this Article XIII, the following
terms shall have the following meanings:

     “Contingent Redemption Payment” means the sum of: (A) the excess, if any, calculated
after the Final Order has been received by the Trustee, of (i) the lesser of (a) $176,385,869.20
and (b) the aggregate amount of the Applicable Premium, as determined in accordance with the Final
Order over (ii) $137,299,262.43, plus (B) interest on such amount from and including February 16,
2011 to but not including the date on which the Contingent Redemption Payment is distributed, at a
rate per annum of 9.125% (computed on the basis of a 360-day year of twelve 30-day months).

     “Court” means the Commercial Division of the Supreme Court of the State of New York,
New York County.

     “Escrow Collateral” means (i) the Secured Escrow Account, including the Escrow Funds
and all Financial Assets credited to the Secured Escrow Account from time to time pursuant to
Section 13.01, (ii) all Securities Entitlements with respect to Financial Assets credited to the
Secured Escrow Account, (iii) all dividends, interest and other payments and distributions,
including any instruments and other property, made on or with respect to any Financial Assets from
time to time received, receivable or credited to the Secured Escrow Account and (iv) all proceeds
of any of the foregoing.

     “Final Order” means the final order of the Court, following the exhaustion of any
appeals to courts of appellate jurisdiction, with respect to the dispute regarding the calculation
of the Applicable Premium, including, but not limited to, the meaning of the language “the
remaining term of the Securities” (as such language is used in the definition of Comparable
Treasury Issue).

     “Financial Assets” has the meaning ascribed to such term in the Uniform Commercial
Code.

     “Second Supplemental Indenture” means the Second Supplemental Indenture dated as of
February 15, 2011 by and between the Company and the Trustee.

3

 

     “Securities Account Control Agreement” means that certain Securities Account Control
Agreement dated as of February 16, 2011 by and among the Company, the Securities Intermediary and
the Trustee, in the form and substance annexed to the Second Supplemental Indenture as Exhibit A.

     “Securities Entitlement” has the meaning ascribed to such term in the Uniform
Commercial Code.

     Section 13.03 Amendments. The provisions of this Article XIII may be amended in
writing by the Company, the Trustee and the Securities Intermediary, with the consent of Eligible
Holders of at least a majority in aggregate principal amount of the Securities.

     Section 13.04 Role of Trustee. The Trustee shall act for the benefit of the Eligible
Holders for purposes of this Article XIII.”

     Section 2.02 Amendment to Section 8.01(c).

     Section 8.01(c) is hereby deleted and replaced in its entirety with the following:

     “(c) Notwithstanding clauses (a) and (b) above, the Company’s and the Trustee’s obligations
in Sections 2.04, 2.05, 2.06, 2.07, 6.05, 6.09, 6.11, 7.02, 7.07, 7.08, 7.09, 8.05 and 8.06 and
Article XIII shall survive until the release of the funds in the Secured Escrow Account in
accordance with Article XIII, provided that, following the discharge of the Indenture, all
references to “Securities” hereunder shall be deemed to mean the right to receive the Contingent
Redemption Payment. Thereafter, the Company’s obligations in Sections 7.07 and 8.05 shall
survive.”

ARTICLE 3

MISCELLANEOUS

     Section 3.01 Ratification of Indenture; Supplemental Indenture

     Part of Indenture.

     (a) Except as expressly supplemented hereby, the Indenture is in all respects ratified and
confirmed and all the terms, conditions and provisions thereof shall remain in full force and
effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every
Holder and Eligible Holder of the Securities heretofore or hereafter authenticated and delivered
shall be bound hereby. In the event of a conflict between the terms and conditions of the
Indenture and the terms and conditions of this Supplemental Indenture, then the terms and
conditions of this Supplemental Indenture shall prevail.

     (b) The provisions of this Supplemental Indenture shall become effective as of the date first
written above and shall become operative immediately prior to the redemption of the Securities.

     Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.

     THIS SUPPLEMENTAL INDENTURE AND THE SECURITIES SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. ALL ACTIONS AND PROCEEDINGS ARISING OUT OF OR
RELATING TO THE INDENTURE, THIS SUPPLEMENTAL INDENTURE, THE SECURITIES OR ANY OF THE TRANSACTIONS
CONTEMPLATED HEREBY SHALL BE HEARD AND DETERMINED EXCLUSIVELY IN THE COMMERCIAL DIVISION OF THE
SUPREME COURT OF NEW YORK

4

 

STATE, NEW YORK COUNTY AND ANY APPELLATE COURT THEREOF. THE PARTIES HERETO HEREBY (I) SUBMIT
TO THE EXCLUSIVE JURISDICTION OF THE ABOVE-NAMED COURTS FOR THE PURPOSE OF ANY ACTION ARISING OUT
OF OR RELATING TO THE INDENTURE, THIS SUPPLEMENTAL INDENTURE, THE SECURITIES OR ANY OF THE
TRANSACTIONS CONTEMPLATED HEREBY, BROUGHT BY ANY PARTY HERETO, AND (II) IRREVOCABLY WAIVE, AND
AGREE NOT TO ASSERT BY WAY OF MOTION, DEFENSE, OR OTHERWISE, IN ANY SUCH ACTION, ANY CLAIM THAT IT
IS NOT SUBJECT PERSONALLY TO THE JURISDICTION OF THE ABOVE-NAMED COURTS, THAT THE ACTION IS BROUGHT
IN AN INCONVENIENT FORUM, THAT THE VENUE OF THE ACTION IS IMPROPER, OR THAT THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY MAY NOT BE ENFORCED IN OR BY ANY OF THE ABOVE-NAMED COURTS.

     EACH OF THE COMPANY, THE TRUSTEE AND THE HOLDERS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THE INDENTURE, THIS SUPPLEMENTAL INDENTURE, THE SECURITIES OR THE
TRANSACTIONS CONTEMPLATED HEREBY.

     Section 3.03 Acknowledgement.

     Upon (i) deposit of the redemption price of $912,495,703.40 for the Securities with the Paying
Agent, (ii) the deposit of the Escrow Funds with the Securities Intermediary, and (iii) the due
execution and delivery of the Securities Account Control Agreement, the conditions precedent to the
satisfaction and discharge of the Indenture pursuant to Section 8.01(a) have been complied with by
the Company.

     Section 3.04 Trustee Makes No Representation.

     The recitals contained herein are those of the Company and not the Trustee, and the Trustee
assumes no responsibility for the correctness of same. The Trustee makes no representations as to
the validity or sufficiency of this Supplemental Indenture. All rights, protections, privileges,
indemnities and benefits granted or afforded to the Trustee under the Indenture shall be deemed
incorporated herein by this reference and shall be deemed applicable to all actions taken, suffered
or omitted by the Trustee under this Supplemental Indenture.

     Section 3.05 No Action.The Company shall take no action against the Trustee
alleging any form of negligence or breach of its obligations or fiduciary duties under the
Indenture, the Notes, the Collateral Agreement or any other Security Document. In addition, the
Company shall not take any action against the Trustee for any malfeasance or other such wrongdoing
in connection with the dispute or resolution of the proper party entitled to the Contingent
Redemption Payment.

     Section 3.06 Counterparts.

     The parties may sign any number of copies of this Supplemental Indenture. Each signed copy
shall be an original, but all of them together represent the same agreement.

5

 

     Section 3.07 Effect of Headings.

     The section headings herein are for convenience only and shall not effect the construction
thereof.

[The remainder of this page is intentionally left blank]

6

 

     IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first written above.

	 	 	 	 	 
	 	US ONCOLOGY, INC.

 	 
	 	By:  	                      /s/ Nicholas A. Loiacono
 	 
	 	 	Name:  	Nicholas A. Loiacono 	 
	 	 	Title:  	Vice President and Treasurer 	 
	 

	 	 	 	 	 
	 	WILMINGTON TRUST FSB,

as Trustee

 	 
	 	By:  	                   /s/ Timothy P. Mowdy
 	 
	 	 	Name:  	Timothy P. Mowdy 	 
	 	 	Title:  	Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]